Peroxisome proliferator-activated receptor γ: A novel target for cancer therapeutics?

Anti-Cancer Drugs

Volumn 18, Issue 3, 2007, Pages 237-244

  Han, ShouWei ^a   Roman, Jesse ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Cancer therapeutics; Kinases; Ligands; Peroxisome proliferator activated receptor ; Signal pathways

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; BCG VACCINE; CIGLITAZONE; CONJUGATED LINOLEIC ACID; FENOPROFEN; FLUFENAMIC ACID; IBUPROFEN; INDOMETACIN; ISOTRETINOIN; LINOLEIC ACID; MEVINOLIN; OMEGA 6 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

APOPTOSIS; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELL TYPE; DIGESTIVE SYSTEM CANCER; DRUG TARGETING; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; INFLAMMATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PPAR GAMMA; TRANSCRIPTION, GENETIC;

EID: 33846653083     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328011e67d     Document Type: Review

References (69)

1. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294:1866-1870.
2. Elangbam CS, Tyler RD, Lightfoot RM. Peroxisome proliferator-activated receptors in atherosclerosis and inflammation: an update. Toxicol Pathol 2001; 29:224-231.
3. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005; 123:993-999.
4. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20:649-688.
5. Qi C, Zhu Y, Reddy JK. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 2000; 32:187-204.
6. Zingarelli B, Cook JA. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 2005; 23:393-399.
7. Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 2006; 533:101-109.
8. 2 on tumor necrosis factor-alpha-induced gene expression. Arterioscler Thromb Vasc Biol 2005; 25:710-716.
9. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferatoractivated receptor gamma-activating properties. J Biol Chem 1998; 273:32679-32684.
10. 2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83:803-812.
11. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4:585-595.
12. Koeffler HP. Peroxisome proliferator-activated receptorγ and cancers. Clin Cancer Res 2003; 9:1-9.
13. Wang T, Xu J, Yu X, Yang R, Han ZC. Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol 2006; 58:1-14.
14. 2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein beta. J Biol Chem 2005; 280:33240-33249.
15. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004; 23:100-108.
16. Lee SY, Hur GY, Jung KH, Jung HC, Lee SY, Kim JH, et al. PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer 2006; 51:297-301.
17. Han S, Sidell N, Fisher PB, Roman J. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res 2004; 10:1911-1919.
18. Han S, Ritzenthaler JD, Rivera HN, Roman J. Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1. Am J Physiol Lung Cell Mol Physiol 2005; 289:L419-L428.
19. 5 integrin gene transcription in non-small cell lung carcinoma cells. Am J Respir Cell Mol Biol 2005; 32:350-359.
20. 2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun 2004; 314:1093-1099.
21. Krysan K, Reckamp KL, Sharma S, Dubinett SM. The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem 2006; 6:209-220.
22. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 2006; 118:773-779.
23. Avis I, Martinez A, Tauler J, Zudaire E, Mayburd A, Abu-Ghazaleh R, et al. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res 2005; 65:4181-4190.
24. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther 2006; 5:430-437.
25. Theocharis S, Kanelli H, Politi E, Margeli A, Karkandaris C, Philippides T, et al. Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer 2002; 36:249-255.
26. Sarraf P, Mueller E, Smith WM, Wright H, Kum J, Aaltonen L, et al. Loss-of-function mutations in PPAR γ associated with human colon cancer. Mol Cell 1999; 3:799-804.
27. Ikezoe T, Miller CW, Kawano S, Heaney A, Williamson EA, Hisatake J et al. Mutational analysis of the peroxisome proliferator-activated receptor γ gene in human malignancies. Cancer Res 2001; 61:5307-5310.
28. Kuniyasu H, Yoshida K, Sasaki T, Sasahira T, Fujii K, Ohmori H. Conjugated linoleic acid inhibits peritoneal metastasis in human gastrointestinal cancer cells. Int J Cancer 2006; 118:571-576.
29. Brockman JA, Gupta RA, DuBois RN. Activation of PPAR γ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998; 115:1049-1055.
30. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y. Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999; 90:75-80.
31. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator activated receptor γ (PPAR γ) ligand induced apoptosis in colon cancer cells. Gut 2002; 50:658-664.
32. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB et al. Differentiation and reversal of malignant changes in colon cancer through PPAR γ. Nat Med 1998; 4:1046-1052.
33. Lu J, Imamura K, Nomura S, Mafune K, Nakajima A, Kadowaki T, et al. Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res 2005; 65:4769-4774.
34. Yang K, Fan KH, Lamprecht SA, Edelmann W, Kopelovich L, Kucherlapati R, et al. Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1 +/- double mutant mice. Int J Cancer 2005; 116:495-499.
35. Chintharlapalli S, Papineni S, Baek SJ, Liu S, Safe S. 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. Mol Pharmacol 2005; 68:1782-1792.
36. Chintharlapalli S, Papineni S, Konopleva M, Andreef M, Samudio I, Safe S. 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways. Mol Pharmacol 2005; 68:119-128.
37. 2 up-regulates Kruppel-like factor 4 expression independently of peroxisome proliferator-activated receptor gamma by activating the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signal transduction pathway in HT-29 colon cancer cells. Mol Pharmacol 2005; 68:1203-1213.
38. Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, et al. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev 2004; 18:528-540.
39. Nunez NP, Liu H, Meadows GG. PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. Cancer Lett 2005; 236:133-141.
40. Papadaki I, Mylona E, Giannopoulou I, Markaki S, Keramopoulos A, Nakopoulou L. PPARgamma expression in breast cancer: clinical value and correlation with ERbeta. Histopathology 2005; 46:37-42.
41. Fenner MH, Elstner E. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opin Investig Drugs 2005; 14:557-568.
42. Huang JW, Shiau CW, Yang YT, Kulp SK, Chen KF, Brueggemeier RW, et al. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol 2005; 67:1342-1348.
43. Lu M, Kwan T, Yu C, Chen F, Freedman B, Schafer JM, et al. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem 2005; 280:6742-6751.
44. 2 induces programmed cell death of breast cancer cells by a pleiotropic mechanism. Carcinogenesis 2005; 26:81-92.
45. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003; 79:391-397.
46. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, et al. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 2004; 13:1710-1716.
47. L/Bcl-2 functions independently of PPARgamma. Cancer Res 2005; 65:1561-1569.
48. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A 2000; 97:10990-10995.
49. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 2000; 60:5494-5498.
50. Shen WT, Chung WY. Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor-gamma agonists. Thyroid 2005; 15:594-599.
51. Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, et al. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 2005; 15:222-231.
52. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther 2004; 3:1011-1020.
53. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000; 289:1357-1160.
54. Guan Y. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease. Minerva Urol Nefrol 2002; 54:65-79.
55. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptorγ (PPARγ) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999; 1:330-339.
56. Fauconnet S, Lascombe I, Chabannes E, Adessi G-L, Desvergne B, Wahli W, Bittard H. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 2002; 277:23534-23543.
57. Nakashiro KI, Hayashi Y, Kita A, Tamatani T, Chlenski A, Ususa N et al. Role of peroxisome proliferator-activated receptor γ and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 2001; 159:591-597.
58. Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM. Inhibition of bladder tumor growth by 1,1-bis(3′-indolyl)-1-(p- substituted phenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res 2006; 66:412-418.
59. Lodillinsky C, Umerez MS, Jasnis MA, Casabe A, Sandes E, Eijan AM. Bacillus Calmette-Guerin induces the expression of peroxisome proliferator-activated receptor gamma in bladder cancer cells. Int J Mol Med 2006; 17:269-273.
60. Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006; 6:53.
61. Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, et al. Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer 2005; 92:113-119.
62. Holland CM, Saidi SA, Evans AL, Sharkey AM, Latimer JA, Crawford RA, et al. Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated receptors as potential therapeutic targets. Mol Cancer Ther 2004; 3:993-1001.
63. Ota K, Ito K, Suzuki T, Saito S, Tamura M, Hayashi S, et al. Peroxisome proliferator-activated receptor gamma and growth inhibition by its ligands in uterine endometrial carcinoma. Clin Cancer Res 2006; 12:4200-4208.
64. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A 1997; 94:237-241.
65. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y, Kinoshita Y. Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents 2004; 4:465-477.
66. Ray DM, Bernstein SH, Phipps RP. Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands. Clin Immunol 2004; 113:203-213.
67. Wang T, Xu J, Yu X, Yang R, Han ZC. Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol 2006; 58:1-14.
68. Zang C, Liu H, Posch MG, Waechter M, Facklam M, Fenner MH et al. Peroxisome proliferator-activated receptorγ ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. Leuk Res 2004; 28:387-397.
69. Konopleva M, Elstner E, McQueen TJ, Tsao T, Sudarikov A, Hu W. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 2004; 3:1249-1262.